Cargando…
Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study
SIMPLE SUMMARY: We aimed to compare the prognosis of patients with advanced hepatocellular carcinoma treated with the first-line atezolizumab plus bevacizumab (AB) combination chemotherapy and the less popular locoregional treatment mainly used in East Asia, hepatic artery infusion chemotherapy (HAI...
Autores principales: | Kim, Ji Hoon, Nam, Hee-Chul, Kim, Chang-Wook, Cho, Hee Sun, Yoo, Jae-Sung, Han, Ji Won, Jang, Jeong Won, Choi, Jong Young, Yoon, Seung Kew, Yang, Hyun, Bae, Si Hyun, Kim, Suho, Oh, Jung Suk, Chun, Ho Jong, Jeon, Chang Ho, Ahn, Jaegyoon, Sung, Pil Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487133/ https://www.ncbi.nlm.nih.gov/pubmed/37686509 http://dx.doi.org/10.3390/cancers15174233 |
Ejemplares similares
-
Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study
por: Lee, Jaejun, et al.
Publicado: (2021) -
A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis
por: Lee, Soon Kyu, et al.
Publicado: (2023) -
Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021) -
Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Kim, Tae Hyun, et al.
Publicado: (2023) -
Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
por: Zhao, Chenghao, et al.
Publicado: (2023)